Ovid Therapeutics OVID 深 滬
已收盤 11-06 16:00:00 美东时间
2.85
+0.270
+10.47%
華盛通- 最 高2.945
- 今 開2.56
- 成交量 389.76万股
- 最 低 2.5585
- 昨 收 2.58
- 總市值 5.57亿
- 52周最高 3.105
- 市盈率 靜 --
- 換手率 2.00%
- 52周最低 1.21
- 委 比 -50.21%
- 總股本 1.95亿
- 歷史最高 15.89
- 量 比 1.56
- 振 幅 14.98%
- 歷史最低 0.2425
- 每 手 1
- 風險率 0.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ovid Therapeutics to Participate in Upcoming Investor Conferences
Ovid Therapeutics announced that its management will participate in three upcoming investor conferences: the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, the Stifel 2026 Healthcare Conference on November 11, and the UBS European Healthcare Conference on November 16. Webcasts of the presentations will be available on the company’s website, investors.ovidrx.com, with archived replays for approximately 30 days.
11-05 13:00
Ovid Therapeutics收涨0.42%，成交额332.19万美元
11月4日，Ovid Therapeutics（OVID）收涨0.42%，报2.4美元，成交额332.19万美元，市值4.7亿美元。 行情数据 • 开盘价：2...
11-04 07:06
Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
Oculis Holding AG has appointed Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer (CSO) and Aaron Tansy, M.D., as Vice President, Development Franchise Head, Neurology. Tackenberg will lead the company's global scientific strategy and advance Privosegtor, a neuroprotective candidate, through its PIONEER registrational program, exploring its potential in acute MS relapses and other neurological indications. Tansy brings expertise in globa...
11-02 07:00
Ovid Therapeutics收涨4.87%，成交额377.59万美元
10月28日，Ovid Therapeutics（OVID）收涨4.87%，报2.26美元，成交额377.59万美元，市值4.41亿美元。 行情数据 • 开盘价...
10-28 06:12
Ovid Therapeutics收跌0.23%，成交额182.56万美元
10月27日，Ovid Therapeutics（OVID）收跌0.23%，报2.15美元，成交额182.56万美元，市值4.21亿美元。 行情数据 • 开盘价...
10-27 06:13
Ovid Therapeutics收跌4.87%，成交额286.59万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:16
美股大行评级 | 潜在涨幅279.75%！Jones Trading维持Contineum Therapeutics(CTNM)"买入"评级，目标价上调至30美元
今日重点评级关注：Jones Trading：维持Contineum Therapeutics"买入"评级，目标价从24美元升至30美元；StoneX：维持Forum Markets"投机性买入"评级，目标价从9美元升至12美元
10-16 12:30
Wolfe Research Initiates Coverage On Ovid Therapeutics with Outperform Rating, Announces Price Target of $5
Wolfe Research initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Outperform rating and announces Price Target of $5.
10-15 20:01
美股大行评级 | 瑞银维持康宁“买入”评级，上调目标价至201美元；大摩维持泛林集团“超配”评级
今日重点评级关注：Needham：维持iRhythm Holdings"买入"评级，目标价从192美元升至194美元；HC Wainwright & Co.：维持5E Advanced Materials"买入"评级，目标价从3.5美元升至6.75美元
10-06 16:45
Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7
Guggenheim analyst Delma Caiati initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $7.
10-06 04:16
